217 related articles for article (PubMed ID: 27405085)
1. Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib.
Dessilly G; Panin N; Elens L; Haufroid V; Demoulin JB
Sci Rep; 2016 Jul; 6():29559. PubMed ID: 27405085
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib.
Dessilly G; Elens L; Panin N; Karmani L; Demoulin JB; Haufroid V
Pharmacogenomics; 2016 Jun; 17(8):883-90. PubMed ID: 27268766
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
4. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
5. Influence of ABCB1 (1236C > T, 2677G > T and 3435C > T) polymorphisms on the transport ability of P-gp-mediated sunitinib in Caco-2 cell line.
Tan DQ
Xenobiotica; 2020 Mar; 50(3):346-353. PubMed ID: 31023123
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
[TBL] [Abstract][Full Text] [Related]
7. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
[TBL] [Abstract][Full Text] [Related]
8. Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.
Sennesael AL; Panin N; Vancraeynest C; Pochet L; Spinewine A; Haufroid V; Elens L
Sci Rep; 2018 Jul; 8(1):10514. PubMed ID: 30002384
[TBL] [Abstract][Full Text] [Related]
9. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
10. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Skoglund K; Boiso Moreno S; Jönsson JI; Vikingsson S; Carlsson B; Gréen H
Pharmacogenet Genomics; 2014 Jan; 24(1):52-61. PubMed ID: 24322003
[TBL] [Abstract][Full Text] [Related]
11. Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.
Yamakawa Y; Hamada A; Uchida T; Sato D; Yuki M; Hayashi M; Kawaguchi T; Saito H
Biol Pharm Bull; 2014; 37(8):1330-5. PubMed ID: 25087954
[TBL] [Abstract][Full Text] [Related]
12. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
[TBL] [Abstract][Full Text] [Related]
13. Continuous Cytostatic Effects of BCR-ABL Tyrosine Kinase Inhibitors (TKIs) after Washout in Human Leukemic K562 Cells.
Aoyama T; Shibayama Y; Furukawa T; Sugawara M; Takekuma Y
Biol Pharm Bull; 2019 Nov; 42(11):1805-1813. PubMed ID: 31434819
[TBL] [Abstract][Full Text] [Related]
14. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
Kosztyu P; Bukvova R; Dolezel P; Mlejnek P
Chem Biol Interact; 2014 Aug; 219():203-10. PubMed ID: 24954033
[TBL] [Abstract][Full Text] [Related]
15. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.
Zheng Q; Wu H; Yu Q; Kim DH; Lipton JH; Angelini S; Soverini S; Vivona D; Takahashi N; Cao J
Pharmacogenomics J; 2015 Apr; 15(2):127-34. PubMed ID: 25245580
[TBL] [Abstract][Full Text] [Related]
16. Effect of four ABCB1 genetic polymorphisms on the accumulation of darunavir in HEK293 recombinant cell lines.
Stillemans G; Djokoto HP; Delongie KA; El-Hamdaoui H; Panin N; Haufroid V; Elens L
Sci Rep; 2021 Apr; 11(1):9000. PubMed ID: 33903659
[TBL] [Abstract][Full Text] [Related]
17. ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro.
Skoglund K; Moreno SB; Baytar M; Jönsson JI; Gréen H
Pharmgenomics Pers Med; 2013; 6():63-72. PubMed ID: 24019750
[TBL] [Abstract][Full Text] [Related]
18. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.
Eadie LN; Saunders VA; Hughes TP; White DL
Leuk Lymphoma; 2013 Mar; 54(3):569-78. PubMed ID: 22845311
[TBL] [Abstract][Full Text] [Related]
19. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene.
Kimchi-Sarfaty C; Marple AH; Shinar S; Kimchi AM; Scavo D; Roma MI; Kim IW; Jones A; Arora M; Gribar J; Gurwitz D; Gottesman MM
Pharmacogenomics; 2007 Jan; 8(1):29-39. PubMed ID: 17187507
[TBL] [Abstract][Full Text] [Related]
20. ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines.
Eadie LN; Hughes TP; White DL
PLoS One; 2016; 11(8):e0161470. PubMed ID: 27536777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
